Latest News for LNAI
Correction Updates a Reference Link; No Other Content in the Original Release Has Changed WILMINGTON, Del. and SACRAMENTO, Calif.
Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5 WILMINGTON, Del. and SACRAMENTO, Calif.
New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering. SACRAMENTO, Calif.
Amended Complaint Alleges 29.6 Million Failed to Deliver Shares and Single Day Trading Volume of 15.3 Times Shares Outstanding, Company Seeks Treble Damages Under Federal RICO Statute WILMINGTON, Del. and SACRAMENTO, Calif.
SACRAMENTO, Calif., June 17, 2026 /PRNewswire/ -- Fellow Shareholders, Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LNAI.
Senate Trading
No Senate trades found for LNAI.
U.S. House Trading
No House trades found for LNAI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.